Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter bought 100,000 shares of the stock in a transaction on Wednesday, December 13th. The shares were bought at an average price of $5.48 per share, with a total value of $548,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Vital Therapies, Inc. (NASDAQ:VTL) opened at $5.55 on Friday. Vital Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $6.50.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. During the same period last year, the company earned ($0.32) EPS. research analysts anticipate that Vital Therapies, Inc. will post -1.26 EPS for the current year.

Several hedge funds have recently modified their holdings of VTL. Dimensional Fund Advisors LP acquired a new position in shares of Vital Therapies during the third quarter worth $116,000. JPMorgan Chase & Co. increased its position in shares of Vital Therapies by 1,985.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock valued at $123,000 after acquiring an additional 24,241 shares during the period. New York State Common Retirement Fund acquired a new position in shares of Vital Therapies in the 3rd quarter valued at $213,000. Dowling & Yahnke LLC acquired a new position in shares of Vital Therapies in the 3rd quarter valued at $252,000. Finally, Goldman Sachs Group Inc. increased its position in shares of Vital Therapies by 1.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after acquiring an additional 1,157 shares during the period. 24.35% of the stock is currently owned by institutional investors and hedge funds.

VTL has been the subject of a number of analyst reports. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday, October 21st. Finally, Raymond James Financial restated a “buy” rating on shares of Vital Therapies in a report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.00.

WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/16/muneer-a-satter-purchases-100000-shares-of-vital-therapies-inc-vtl-stock.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Stock Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related stocks with our FREE daily email newsletter.